Age: 1.0
Sex: F
Vaccine: HEPA, HIBV, MMR, MMRV, PNC15
Symptoms: Roseola, Vomiting
Clinical narrative: Roseola/rash/fever; HCP called to report inadvertent administration of both PROQUAD and MMR-II to a 12-month-old patient on 22APR2024. No prior doses of either PROQUAD or MMR-II have been administered.; vomiting; This spontaneous report was received from a registered nurse, referring to a 12-month-old female. The patient's medical history included developmental delay, and haemangioma of skin. The patient's concurrent conditions were not provided. There were no concomitant medications listed. There were no vaccines with 4 weeks of administration. There were no prior adverse events related to vaccinations for the patient or sibling. The patient has no known drug allergies.  On 22-APR-2024, the patient was vaccinated with the first dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live, recombinant Human albumin (rHA) (PROQUAD) injection, lot #X025093 has been verified to be a valid lot number, expiration date was reported and validated as 16-APR-2025, administered intramuscularly on the right thigh for prophylaxis (strength and dose were not provided); the first dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live, recombinant Human albumin (rHA) (M-M-R II) subcutaneous injection, lot #W032493 has been verified to be a valid lot number, expiration date was reported and validated as 11-OCT-2024, administered subcutaneously on the left thigh for prophylaxis (strength and dose were not provided); the first dose of hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, lot #X020849 has been verified to be a valid lot number, expiration date was reported and validated as 26-DEC-2024, administered intramuscularly on the right thigh for prophylaxis (strength and dose were not provided); the fourth dose of pneumococcal 15v conj vaccine (crm197) (VAXNEUVANCE) injection, lot #X022028 has been verified to be a valid lot number, expiration date was not reported and upon internal validation established as 22-OCT-2025, administered intramuscularly on the left thigh for prophylaxis (strength and dose were not provided); and the fourth dose of hib vaccine conj (tet tox) (ACT HIB) (manufacture unknown), lot# was reported as UJ965AA, expiration date was reported as 08-NOV-2024, administered intramuscularly on the right thigh for prophylaxis (strength, formulation, and dose were not provided). The vaccines were administered by a certified medical assistant who was trained to administered vaccines. The administration of both measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) was inadvertent (accidental overdose). No prior doses of either measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) have been administered. The vaccines were administered in a public care facility and the vaccine was purchased with public funds.  On an unknown day in 2024, vomiting began. The patient began with a fever on 29-APR-2024. On 01-MAY-2024, (reported as yesterday), the patient was seen in the nurse's office.  The patient was afebrile with 97.9 degree Fahrenheit at office visit. The patient had an onset of rash on 01-MAY-2024. The patient had a faint pink blanchable papular rash on the trunk and some scattered macules on the arms and legs. The diagnosis given was Roseola. Vital signs were stable. The patient was eating well, hydrated, and active. The patient's condition was non-urgent or emergent. The patient did not require any treatment for complaints according to the physician. The outcome of roseola and vomiting was not provided. The action taken with all suspect therapies regarding the events of roseola and vomiting was not provided.  The causality between all suspect vaccines regarding the events of roseola and vomiting was not provided.